Related Experiment Video
Updated: May 23, 2025
Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen
Published on: May 12, 2023
Personalized immunization against Mpox Clades I and Ib: Strategies to combat the emerging epidemic
Deepak Kumar1, Rishabha Malviya1,2, Shriyansh Srivastava1
1Department of Pharmacy, School of Medical and Allied Sciences, Galgotias University, Greater Noida 203201, India.
Abstract:
Mpox, formerly known as monkeypox, is a zoonotic virus of the Orthopoxvirus genus, with recent outbreaks of Clade I and Ib in Central Africa presenting a considerable global health threat. This study reviews current Mpox immunization approaches, focusing on the MVA-BN, LC16-KMB, and OrthopoxVac vaccines. MVA-BN vaccination has been successful in lowering infection risks, particularly in high-risk individuals and is widely used in the USA. LC16-KMB is recommended by the World Health Organization for prevention in afflicted regions. OrthopoxVac, a newer vaccination authorized in Russia, provides wide protection. Adapting vaccination approaches based on epidemiology in particular areas is critical for minimizing Mpox outbreaks.
Insights
Mpox (formerly monkeypox) outbreaks are a global health concern. This review covers MVA-BN, LC16-KMB, and OrthopoxVac vaccines, highlighting their roles in mitigating infection risks and the need for tailored vaccination strategies.
Area of Science:
- Virology
- Epidemiology
- Public Health
Background:
- Mpox, a zoonotic virus from the Orthopopoxvirus genus, poses a significant global health threat due to recent Clade I and Ib outbreaks.
- Central Africa has been particularly affected by these outbreaks, necessitating urgent public health interventions.
Purpose of the Study:
- To review current immunization strategies for Mpox.
- To evaluate the efficacy and application of key vaccines: MVA-BN, LC16-KMB, and OrthopoxVac.
- To emphasize the importance of geographically tailored vaccination approaches.
Main Methods:
- Literature review of current Mpox vaccination approaches.
- Analysis of vaccine efficacy and deployment in different regions.
- Synthesis of epidemiological data to inform vaccination strategies.
Main Results:
- MVA-BN vaccination demonstrates success in reducing Mpox infection risks, especially for high-risk groups, and is widely used in the USA.
- LC16-KMB vaccine is recommended by the WHO for prevention in endemic areas.
- OrthopoxVac, a Russian-approved vaccine, offers broad protection against Mpox.
Conclusions:
- Current Mpox vaccines like MVA-BN, LC16-KMB, and OrthopoxVac offer viable options for outbreak control.
- Adapting vaccination strategies to local epidemiological contexts is crucial for effective Mpox outbreak minimization.
- Continued research and surveillance are vital for optimizing global Mpox prevention efforts.
